

Stefanie A De Boer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5999907/publications.pdf>

Version: 2024-02-01

8
papers

115
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

217
citing authors

#	ARTICLE	IF	CITATIONS
1	Arterial Stiffness Is Positively Associated With 18F-fluorodeoxyglucose Positron Emission Tomography—Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes. Diabetes Care, 2016, 39, 1440-1447.	8.6	34
2	Effect of linagliptin on pulse wave velocity in early type 2 diabetes: <sc>A</sc> randomized, double-blind, controlled 26-week trial (<sc>RELEASE</sc>). Diabetes, Obesity and Metabolism, 2017, 19, 1147-1154.	4.4	33
3	Visceral adipose tissue volume is associated with premature atherosclerosis in early type 2 diabetes mellitus independent of traditional risk factors. Atherosclerosis, 2019, 290, 87-93.	0.8	20
4	Effect of Linagliptin on Arterial 18 F-Fluorodeoxyglucose Positron Emission Tomography Uptake. Journal of the American College of Cardiology, 2017, 69, 1097-1098.	2.8	8
5	[18F]FDG Uptake in Adipose Tissue Is Not Related to Inflammation in Type 2 Diabetes Mellitus. Molecular Imaging and Biology, 2021, 23, 117-126.	2.6	8
6	Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin: A subanalysis from a randomized, placebo-controlled trial (RELEASE) Tj ETQq0 0.0 rgBT /Overlock 10	0.0	0
7	Performance Evaluation of a Semi-automated Method for [18F]FDG Uptake in Abdominal Visceral Adipose Tissue. Molecular Imaging and Biology, 2019, 21, 159-167.	2.6	3
8	Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus. Antioxidants, 2021, 10, 1548.	5.1	2